Always appreciate your views and opinions Shell. We do have...

Always appreciate your views and opinions Shell. We do have opposing views on this. In relation to the CORE-NK trial: The first patient was dosed in February 2024, some 14 months ago. Six patients were dosed by the end of June '24.

In my humble opinion, it is entirely reasonable for shareholders and the market to expect some form of efficacy data from a company after 14 months of a dose-finding stage, especially if the trial has already progressed to a frontline indication.

Here’s why:

1. Timeframe:

Fourteen months in a dose-finding trial — even with a small cohort — typically yields some preliminary data. While the primary aim is safety and optimal dosing, early signals of efficacy are often observed, tracked, and can be ethically disclosed, particularly when:

• A drug progresses into frontline treatment (which usually requires some justification based on results),

• The company continues to raise capital and needs to maintain transparency with investors,

There are market-sensitive implications (e.g., moving into a broader patient population without showing why).

2. Material disclosure obligations:

If the company is:

• Advancing a product into a new phase of development,

• Presenting or planning to present at conferences like ASH (American Society of Hematology),

Then it may be withholding market-sensitive information, especially if efficacy signals exist — which it likely would need in order to advance the program.

In October 2024, Rebecca said herself that they "should see some data shortly from the AML program." Also, back in July '24 Rebecca also said to expect data readouts from the AML trial. Therefore I don't believe it's unreasonable to expect data/efficacy based on these comments. She also said in the October interview "With all the positive newsflow coming, the only way is up." Well, there's been a distinct lack of newsflow and the way we have gone is down.

I'm aware of the continuous disclosure provisions and I don't believe that any exemptions exist.

Rebecca has been in the role of CEO since the 24th May 2024 after Jennifer Chow vacated that position. The share price was already in a decline but despite her comments, the share price has continued its downward spiral. I don't believe it is solely her fault. She obviously has to work with the Board so she faces an uphill battle on that front!

What is suspicious about raising the subject now?

I'm sorry if my activism towards management is causing you anguish. I am honestly. But if no one holds these people to account then retail shareholders will be the only losers - as we already are.